Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7893)	11/30/1998 9:27:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Love the U.S. Patent Office site. So much better than the IBM site. Opalapril will be pleased to know there is something about the government I like. Patent 5,837,678, excerpt: SUMMARY OF THE INVENTION According to one aspect of the invention, methods are provided for neutralizing the anti-coagulant activity of heparin comprising administering an effective amount of a BPI protein product in vivo to a subject or in vitro to a fluid sample containing heparin. According to another aspect of the invention, a BPI protein product is administered to subjects in order to inhibit endothelial cell proliferation including but not limited to endothelial cell proliferation associated with angiogenesis. The invention provides methods of inhibiting angiogenesis associated with a variety of clinical conditions. Specifically provided by the invention are methods of treating cancer by inhibiting angiogenesis associated with malignant tumor proliferation; Kaposi's sarcoma lesions and the like. Cancers susceptible to treatment by administration of BPI protein products include melanoma, sarcomas, and carcinomas including but not limited to breast, colon, lung, and prostate carcinomas. Other conditions for which BPI protein products can be administered for inhibition of angiogenesis include ocular retinopathy, retrolental fibroplasia, psoriasis, angiofibromas, endometriosis, hemangiomas and the like. Also contemplated by the invention are methods of contraception comprising delivering of an effective amount of a BPI protein product so as to prevent implantation of a fertilized ovum. The invention also provides methods of treating chronic inflammatory disease states such as arthritis, psoriasis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, lupus erythematosus, autoimmune uveitis, Lyme disease, and asthma comprising administering an effective amount of a BPI protein product to a subject suffering from the inflammatory disease state. The invention also provides methods of preparation of medicaments for neutralization of the anti-coagulant properties of heparin, inhibition of tumor and endothelial cell proliferation, inhibition of angiogenesis and treatment of chronic inflammatory disease states. Such medicaments can be prepared for oral administration for injection or other parenteral methods and preferably include conventional pharmaceutically acceptable carriers and adjuvents as would be known to those of skill in the art. The medicaments are preferably in the form of a unit dose in solid, semi-solid and liquid dosage forms such as tablets, pills, powders, liquid solutions or suspensions, and injectable and infusible solutions. Effective dosage ranges from about 100 .mu.g/kg to about 10 mg/kg of body weight are contemplated. As used herein, "BPI protein product" includes naturally and recombinantly produced bactericidal/permeability-increasing protein; natural, synthetic, and recombinant biologically active polypeptide fragments of bactericidal/permeability increasing protein; and biologically active polypeptides or analogs, including hybrid fusion proteins, of either bactericidal/permeability increasing protein or biologically active fragments thereof.

To: Bluegreen who wrote (7893)	12/1/1998 3:16:00 AM
From: Tharos	Respond to of 17367

Yes it does if: -stock is being manipulated by market makers -Xoma has done a remarkable job at keeping information from leaking to public

To: Bluegreen who wrote (7893)	12/1/1998 5:11:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

XOMA site updated. Have not read came back to beat RobertK. xoma.com

To: Bluegreen who wrote (7893)	12/1/1998 5:55:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Bluegreen, I am voting YES. Why don't large pharmas do it? This is clearly explained. Once the fair value of the assets of a company are high, this type of action becomes almost impossible because of the one time tax consequences. While I don't speak for Amgen, one can surmise, (correctly or incorrectly), that they are doing all they can, as evidenced by their 3 Bermuda, affiliates to at least get some of the benefits. Advise everyone who owns shares to read the prospectus. Appreciate XOMA's management for thinking beyond the box. Clearly this is one way to add value for the shareholders, IMO, but obviously this will only be true if XOMA's drugs are approved and are a commercial success.